Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901678 | 0.92 | TSHR (0.81) | TSHRCYP19A1CYP4F2CYP4A11MEN1 | |
| SCHEMBL9626909 | 0.85 | TSHR (0.70) | TSHRCYP19A1MEN1CRHBPKMT2A | |
| SCHEMBL5175026 | 0.85 | TSHR (0.76) | TSHRCYP19A1MEN1CRHBPKMT2A | |
| SCHEMBL10309729 | 0.85 | TSHR (0.70) | TSHRCYP19A1MEN1CRHBPKMT2A | |
| SCHEMBL27455918 | 0.83 | TSHR (0.68) | TSHRCYP19A1MEN1CRHBPKMT2A | |
| SCHEMBL29197989 | 0.83 | TSHR (0.68) | TSHRCYP19A1CYP4F2CYP4A11MEN1 | |
| SCHEMBL27255868 | 0.83 | TSHR (0.68) | TSHRCYP19A1MEN1CRHBPKMT2A | |
| SCHEMBL10369206 | 0.83 | TSHR (0.68) | TSHRCYP19A1MEN1KMT2APOLB | |
| SCHEMBL873430 | 0.82 | TSHR (1.00) | TSHRCYP19A1POLBKLK7ALDH1A1 | |
| SCHEMBL16346002 | 0.82 | TSHR (0.62) | TSHRCYP4F2CYP4A11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326224-A1 | COMPOSITION FOR TREATING A KERATINOUS SURFACE | Givaudan SA (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-20080287396-A1 | Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections | TARGANTA THERAPEUTICA INC. (CA) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287396-A1 | Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections | BPGM, PSPH, PGLS | TSHR 4446/4885CYP19A1 3646/4885CYP4F2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.